A phase 2,24-week,randomized,placebo-controlled,double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis
Restricted accessResearch articleFirst published online February, 2011
A phase 2,24-week,randomized,placebo-controlled,double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis
Background: Interleukins 12 and 23 (IL-12/23) have been implicated in multiple sclerosis (MS) pathogenesis. This study assessed the efficacy and safety of ABT-874, a monoclonal anti-IL-12/23 antibody, in active relapsing–remitting MS (RRMS) or secondary progressive MS (SPMS).
Methods: In this 24-week study, patients with RRMS or SPMS received ABT-874 200 mg every other week (EOW), ABT-874 200 mg every week (EW), or placebo. The cumulative number of gadolinium-enhanced lesions, relapse rate, disability progression, and adverse events were measured.
Results: 215 patients were randomized (ABT-874 200 mg EOW, N = 76; ABT-874 200 mg EW, N = 70; placebo, N = 69). At week 24, gadolinium-enhanced lesions were statistically significantly reduced with ABT-874 200 mg EOW vs. placebo (mean number [SD]: 5.4 [8.1] vs. 7.6 [14.4], p = 0.003), but not with ABT-874 200 mg EW (6.8 [11.3], p = 0.134). Mean relapse rate (relapses/y) was significantly lower for ABT-874 200 mg EW vs. placebo (0.1 [95% CI −0.0, 0.3] vs. 0.5 [0.2, 0.8], p = 0.007). Changes from baseline in disability scores and incidences of adverse events were not significantly different across treatment groups, although a numerically greater percentage of serious adverse events was reported for ABT-874 treatment groups.
Conclusions: Although rates of adverse events were not significantly different between ABT-874 treatment groups and placebo, the magnitude of ABT-874 efficacy was less than that observed with other agents currently in development for MS treatment. Anti-IL-12/23 monotherapy does not appear to warrant further testing as monotherapy treatment for MS.
VandenbroeckKAllozaIGadinaMMatthysP. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol2004; 2: 145–160.
4.
KangBYKimTS. Targeting cytokines of the interleukin-12 family in autoimmunity. Curr Med Chem2006; 10: 1149–1156.
5.
OppmannBLesleyRBlomBTimansJCXuYHunteB. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity2000; 5: 715–725.
6.
AggarwalSGhilardiNXieMHde SauvageFJGurneyAL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem2003; 3: 1910–1914.
GatelyMKRenzettiLMMagramJSternASAdoriniLGublerU. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol1998; 495–521.
9.
MosmannTRCoffmanRL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol1989; 145–173.
10.
SospedraMMartinR. Immunology of multiple sclerosis. Annu Rev Immunol2005; 683–747.
11.
KebirHKreymborgKIferganIDodelet-DevillersACayrolRBernardM. Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat Med2007; 10: 1173–1175.
12.
LangrishCLChenYBlumenscheinWMMattsonJBashamBSedgwickJD. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med2005; 2: 233–240.
BrokHPvan MeursMBlezerESchantzAPerittDTreacyG. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol2002; 11: 6554–6563.
15.
HartBATBrokHPRemarqueEBensonJTreacyGAmorS. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human–anti-human IL-12p40 antibody. J Immunol2005; 7: 4761–4768.
16.
KasperLHEverittDLeistTPRyanKAMascelliMAJohnsonK. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin2006; 9: 1671–1678.
17.
McDonaldWICompstonAEdanGGoodkinDHartungHPLublinFD. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol2001; 1: 121–127.
18.
SegalBMConstantinescuCSRaychaudhuriAKimLFidelus-GortRKasperLH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing–remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol2008; 9: 796–804.
19.
Paulson SK, Hrusk M, Valdes J and Awni W. The pharmacokinetics of a fully human interleukin-12/23 monoclonal antibody (ABT 874) in normal healthy volunteers. In: (ed.) Proceedings from the 17th Congress of European Academy of Dermatology and Venereology, 17–21 September 2008, Paris, France. J Am Academy of Dermatology 2009; 60; suppl 1: AB168, DOI: 10.016/j.jaad.2008.11.732, abstract 1389.
LongbrakeEERackeMK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?Expert Rev Neurother2009; 3: 319–321.
22.
ThakkerPLeachMWKuangWBenoitSELeonardJPMarusicS. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol2007; 4: 2589–2598.
23.
KapposLAntelJComiGMontalbanXO’ConnorPPolmanCH. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med2006; 11: 1124–1140.
24.
MillerDHKhanOASheremataWABlumhardtLDRiceGPLibonatiMA. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2003; 1: 15–23.
